Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

Status unconfirmed · Phase 2

Conditions studied: Biliary Atresia

In brief

The Investigators propose to test the hypothesis that GCSF enhances the clinical outcome of biliary atresia in a multi-institutional Phase 2 trial to prospectively evaluate the safety and efficacy of GCSF in each of the 2 groups of newly diagnosed BA patients: KBA (i.e., Kasai-operated) or NoK (i.e., patients who did not undergo Kasai surgery). Subjects who participate in the trial will be followed for 2 years.

Key facts

Study ID
NCT04373941
Run by
Holterman, Ai-Xuan, M.D.
People needed
400
Starts
2023-09-01
Expected to finish
2025-10-31
Last updated by the study team
2023-09-08

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.